Estrogen and vascular resistance

Current Opinion in Endocrinology and Diabetes

Volumn 6, Issue 3, 1999, Pages 218-224

  Barton, Matthias ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEMBRANE RECEPTOR; NITRIC OXIDE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MALE; MEMBRANE POTENTIAL; MENOPAUSE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK FACTOR; VASCULAR RESISTANCE;

EID: 0032987953     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199906000-00009     Document Type: Article

References (132)

1. NIH Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health; 1992.
2. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991, 325:726-762.
3. Farhat MY, Lavigne MC, Ramwell PW: The vascular protective effects of estrogen. FASEB J 1996, 10:615-624.
4. Fahreus L: The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1988, 72 (suppl):18S-22S.
5. Barrett-Connor E, Bush T: Estrogen and coronary heart disease in women. JAMA 1991, 265:1861-1867.
6. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, et al.: Menopause is associated with endothelial dysfunction in women. Hypertension 1996, 28:576-582.
7. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
8. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB: Estrogen regulation of angiotensin converting enzyme mRNA. Hypertension 1999, 33:323-328. This was the first study to demonstrate the inhibition of angiotensin-converting enzyme mRNA expression by estrogen.
9. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al.: Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997, 336:683-690.
10. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K: Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol 1999, 19:67-72.
11. Polderman KH, Stehouwer CD, van Kamp GI, Dekker GA, Verheugt FW, Gooren LJ: Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993, 118:429-432.
12. 2+ mobilization. Circ Res 1997, 81:885-892. This important study shows that endothelial NOS is rapidly regulated by 17β-estradiol in a calcium-independent manner. This contrasts with the current concept of calcium-dependent regulation of NOS 3.
13. Weiner P, Lozasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S: Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A 1994, 91:5212-5216.
14. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, et al.: Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender differences and effect of estrogen receptor disruption. J Clin Invest 1997, 99:2429-2937.
15. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 299:373-376.
16. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265-9269.
17. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663-665.
18. Dzau VJ: Significance of the vascular renin-angiotensin pathway. Hypertension 1986, 8:553-559.
19. Lüscher TF, Vanhoutte PM: The Endothelium: Modulator of Cardiovascular Function. Boca Raton, FL: CRC Press; 1990.
20. Busse R, Lückhoff A, Bassenge E: Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-Schmiedebergs Arch Pharmacol 1987, 336:566-571.
21. Sneddon JM, Vane JR: Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A 1988, 85:2800-2804.
22. Förstermann U, Boissel JP, Kleinert H. Expressional control of the "constitutive" isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998, 12:773-790.
23. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T: Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995, 360:291-293.
24. Hayashi TJ, Fukuto JM, Ignarro U, Chaudhuri G: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: Implications for atherosclerosis. Proc Natl Acad Sci U S A 1992, 89:11259-11263.
25. Hayashi T, Fukoto JM, Ignarro LJ, Chaudhuri G: Gender differences in atherosclerosis: Possible role of nitric oxide. J Cardiovasc Pharmacol 1995, 26:792-802.
26. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, et al.: Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995, 214:847-855.
27. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Förstermann U: Estrogens increase transcription of the human endothelial NO synthase gene. Analysis of the transcription factors involved. Hypertension 1998, 31:582-588.
28. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, Shaul PW: Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997, 81:355-362.
29. Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.
30. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
31. Lüscher TF: The endothelium as a target and mediator of cardiovascular disease. Eur J Clin Invest 1993, 23:670-685.
32. Masaki T: Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995, 235-255.
33. Lecoin L, Sakurai T, Ngo M, Abe Y, Yanagisawa M, Le Douarin NM: Cloning and characterization of a novel endothelin receptor subtype in the avian class. Proc Natl Acad Sci U S A 1998, 95:3024-3029.
34. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VL: Molecular characterization of a dual endothelin-1/angiotensin II receptor. Mol Med 1998, 4:96-108.
35. A receptor antagonist BO123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol 1992, 225:347-350.
36. Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 1990, 85:587-590.
37. B receptor in rabbit mesenteric arteries. Am J Physiol 1999, 276:383-390.
38. Yokokawa K, Kohno M, Yasunari K, Murakawa K, Takeda T: Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells. Hypertension 1991, 18:304-315.
39. Stewart DJ, Langleben D, Cernacek P, Cianflone K: Endothelin release is inhibited by coculture of endothelial cells with cells of vascular media. Am J Physiol 1990, 259:H1928-H1932.
40. Malek AM, Greene AL, Izumo S: Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 1993, 90:5999-6003.
41. Barton M, Shaw S, Hishikawa K, Joch H, Lüscher TF: Estrogen inhibits endothelin production in human endothelial cells: Evidence for NO-independent, estrogen-receptor mediated mechanisms and thrombin-mediated superoxide release [abstract]. J Am Coll Cardiol 1998, 31:213A.
42. Bu X, Su M, Covington JW, Quertermous T, Vaughan DE: Estrogen receptors (ER-α and ER-β) down-regulate ET-1 gene expression through GATA and AP-1 binding sites in endothelial cells [abstract]. Circulation 1998, 98:1-746
43. A. antagonist. Circulation 1997, 96:1593-1597.
44. A receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31:499-504.
45. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoe-deficient mice. Proc Natl Acad Sci U S A 1998, 95:14367-14372.
46. Chamness GC, Jennings AW, McGuire WL: Estrogen receptor binding is not restricted to target nuclei. Nature 1973, 241:458-460.
47. Herwitz KB, Horwitz LD: Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 1982, 69:750-780.
48. Karas RH, Baur WE, van Eickles M, Mendelsohn ME: Human vascular smooth muscle cells express an estrogen receptor isoform. FEBS Lett 1995, 377:103-108.
49. Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994, 89:1943-1950.
50. Orimo A, Inoue S, Ouchi Y, Orimo H: Vascular smooth muscle cells possess estrogen receptor and respond to estrogen. Ann N Y Acad Sci 1995, 746:592-594.
51. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, et al.: Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996, 94:1402-1407.
52. Venkov CD, Rankin AB, Vaughan DE: Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996, 94:727-733.
53. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM, Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994, 89:1501-1510.
54. Inoue S, Hoshino SJ, Miyoshi H, Akishita M, Hosol T, Crime H, Ouchi Y: Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle. Biochem Biophys Res Commun 1996, 219:766-772.
55. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JÅ: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
56. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, et al.: The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ER α in vivo and in vitro. Biochem Biophys Res Commun 1998, 243:122-126. This important study reports the identification of the structure of human ERβ and presents evidence of cross-talk between ERα and ERβ
57. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al.: Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998, 247:75-78.
58. Iafrati MD, Kara RD, Aronovitz M, Kim S, Sullivan TR, Lubahn DB, et al.: Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med 1997, 3:545-548. This work first suggested that ERβ has a functional role in mediation of the antiproliferative effects of estrogen in the vasculature after balloon injury of the carotid artery in mice.
59. Lindner V, Kim SK, Kara RH, Kuiper GGJM, Gustafsson JÅ, Mendelsohn ME: Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 1998, 83:224-229. This interesting study demonstrates marked upregulation of ERβ mRNA in response to balloon angioplasty in carotid arteries of male rats, suggesting a sex-independent function of ERβ.
60. Kuiper GGJM, Carlquist M, Gustafsson JÅ: Estrogen is a male and female hormone. Sci Med 1998, 5:36-45.
61. Register TC, Adams MR: Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 1998, 64:187-191.
62. Colburn P, Bounassisi V: Estrogen-binding sites in endothelial cell cultures. Science 1978, 201:817-819.
63. Thampan TNRV, Clark JH: An estrogen receptor activator protein in rat uterine cytosol. Nature 1981, 290:152-154.
64. Harder DR, Coufson PB: Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth cells. J Cell Physiol 1979, 100:375-382.
65. Jiang C, Sarrel P, Lindsay D, Poole-Wilson P, Collins P: Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 1991, 104:1033-1037.
66. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen M: Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro. Cardiovasc Res 1993, 27:1939-1942.
67. Barton M, Cremer J, Mügge A: 17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in human coronary arteries. Eur J Pharmacol 1998, 362:73-76.
68. Rusko J, Li L, van Breemen C: 17-beta-estradiol stimulation of endothelial K+ channels. Biochem Biophys Res Commun 1995, 214:367-372.
69. Kitazawa T, Hamada E, Kitazawa K, Gaznabi AKM: Non-genomic mechanism of 17β-estradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 1997, 499:497-511.
70. Pappas TO, Gametchu B, Watson CS: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 1995, 9:404-410.
71. Benten WPM, Lieberherr M, Sekeris CE, Wunderlich F: Testosterone induces Ca 2+ influx via non-generate surface receptors in activated T-cells. FEBS Lett 1997, 407:211-214.
72. Falkenstein E, Meyer C, Eisen C, Scriba PC, Wehling M: Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem Biophys Res Commun 1996, 229:86-89.
73. Wehling M: Specific, nongenemic actions of steroid hormones. Annu Rev Physiol 1997, 59:365-393.
74. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW: Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997, 973:L119-L126.
75. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW: Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103:401-406. This very interesting study shows that ERα, which is thought to mediate the genomic actions of estrogens, is involved in the rapid, nongenomic activation of endothelial NOS by estrogen.
76. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE: Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999, 96:2788-2793.
77. MacKenzie JN: Irritation of the sexual apparatus. Am J Mod Sci 1884, 87:360.
78. Markee JD: Rhythmic vascular uterine changes. Am J Physiol 1932, 100:32-39.
79. Wang X, Barber DA, Lewis DA, McGregor CGA, Sieck GC, Fitzpatrick LA, Miller VA: Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial ceils. Am J Physiol 1997, 273:H1962-H1967.
80. Caulin-Glaser T, Watson CA, Pardi R, Bender JR: Effects of 17β-estradiol on cytokine-induced endothelial cells adhesion molecule expression. J Clin Invest 1996, 98:36-42.
81. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, Levin ER: Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 1998, 330:1097-1105. This was the first study to investigate the molecular mechanisms by which estrogen and progesterone inhibit angiotensin II-induced formation of ET-1 in bovine aortic endothelial cells.
82. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM: Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993, 92:2867-2871.
83. De Beer EL, Keizer HA: Direct action of estradiol-17β on the atrial action potential. Steroids 1982, 40:223-231.
84. Sudhir K, Ko E, Zellner C, Wong HE, Hutchinson SJ, Chou TM, Chatterjee K: Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 1997, 96:3626-3632.
85. Madeddu P, Emanueli C, Varoni MV, Demontis MP, Anania V, Gorioso N, Chao J: Regulation of bradykinin B2-receptor expression by oestrogen. Br J Pharmacol 1997, 121:1763-1769.
86. Barber DA, Sieck GC, Fitzpatrick LA, Miller VA: Endothelin receptors are modulated in association with endogenous fluctuations of estrogen. Am J Physiol 1996, 271:H1999-H2006.
87. Ergul A, Shoemaker K, Puett D, Tackett RL: Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 1998, 285:511-517. This study suggests the regulation of endothelin receptor expression by sex steroid in human arteries and veins.
88. Ahokas RA, Sibai BM: Endothelium-derived relaxing factor inhibition augments vascular angiotensin II reactivity in the pregnant rat hind limb. Am J Obstet Gynecol 1992, 167:1053-1058.
89. Mügge A, Barton M, Fieguth HG, Riedel M: Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-oestradiol in human internal mammary arteries in vitro. Pharmacology 1997, 54:162-168.
90. Andersen HL, Weis JU, Fjalland B, Korsgaard N: Effect of acute and long-term treatment with 17β-estradiol on the vasomotor responses in the rat aorta. Br J Pharmacol 1999, 126:159-168.
91. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, et al.: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995, 91:755-763.
92. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC: Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995, 346:89-90.
93. Tanaka M, Nakaya S, Watanabe M, Kumai T, Tateishi T, Kobayashi S: Effects of ovariectomy and estrogen replacement on aorta angiotensin-converting enzyme activity in rats. Jpn J Pharmacol 1997, 73:361-363. This was the first study to show that estrogen can inhibit angiotensin-converting enzyme activity in tissue.
94. Sugioka K, Shimosegawa Y, Nakano M: Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987, 210:37-39.
95. Negre-Salvayre A, Pieraggi MT, Mabile L, Salvayre R: Protective effect of 17 beta-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993, 99:207-217.
96. Arnal JF, Clamens S, Pechet C, Negre-Salvayre A., Allera C, Girolami JP, et al.: Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide production. Proc Natl Acad Sci U S A 1996, 93:4108-4113.
97. Brandes RP, Mügge A: Gender differences in the generation of superoxide anions in the rat aorta. Life Sci 1997; 60:391-396.
98. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, et al.: Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995, 92:3431-3435.
99. Silva de Sa MF, Meirelles RS: Vasodilating effect of estrogen on the human umbilical artery. Gynecol Invest 1977, 8:307-313.
100. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P: Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis 1995, 6:417-422.
101. Williams JK, Adams MR, Klopfenstein HS: Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990, 81:1680-1687.
102. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
103. Herrington DM, Braden GA, Williams JK, Morgan TM: Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without replacement therapy. Am J Cardiol 1994, 73:951-952.
104. Williams JK, Anthony MS, Honore EK, Herrington DM, Morgan TM, Register TC, Clarkson TB: Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995, 15:827-836.
105. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936-941.
106. Huang A, Sun D, Koller A, Kaley G: Gender differences in flow-induced dilation and regulation of shear stress. Role of estrogen and nitric oxide. Am J Physiol 1998, 275:R1571-R1577. This study provides evidence to show that estrogen is involved in shear stress-induced regulation of vascular tone.
107. Bush DE, Jones CE, Bass KM, Walters GK, Bruza JM, Ouyang P: Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998, 104:552-558.
108. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, et al.: Estradiol therapy combined with progesterone and endothelium-dependent vasodilatation in postmenopausal women. Circulation 1998, 98:1158-1163.
109. Koh KK, Cardillo C, Bui M, Hathaway L, Csako G, Waclacic MA, et al.: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999, 99:354-360. This study compared the effect of cholesterol-lowering medication with that of estrogen on endothelium-dependent vasomotion in the forearm and on cardiovascular risk factors in postmenopausal women.
110. Sorensen KE, Dorup I, Hermann AP, Mosekilde L: Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998, 95:76-82.
111. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K: Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997, 3:324-328.
112. McCrohon JA, Walter WAW, Robinson JTC, McCredie RJ, Turner L, Adams MR, et al.: Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997, 29:1432-1436.
113. New G, Timmins KL, Duffy SJ, Tran BT, O'Brien RC, Harper RW, Meredith IT: Long-term estrogen improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997, 27:1437-1444.
114. Reis SE, Holubkov R, Zell KA, Smith AH, Cohen HA, Feldman MD, Blumenthal RS: Estrogen acutely abolishes abnormal cold-induced coronary constriction in men. Chest 1998, 114:1556-1561.
115. Reis SE, Bhooplalam V, Zell KA, Counihan PJ, Smith AJC, Pham S, Murali S: Conjugated estrogens acutely abolish abnormal cold-induced coronary vasoconstriction in male cardiac allografts. Circulation 1998, 97:23-25.
116. Blumenthal RS, Heldman AW, Brinker JA, Resar JR, Coombs VJ, Gloth ST, et al.: Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men. Am J Cardiol 1997, 80:1021-1024.
117. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, et al.: Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996, 28:1111-1118.
118. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, et al.: Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995, 96:2482-2488.
119. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD: Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1-5.
120. Abu-Halawa SA, Thompson K, Kirkeeide RL, Vaughn WK, Rosales O, Fujisi K, et al.: Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol 1998, 82:409-413. This was the first study to provide evidence for the inhibitory effects of estrogen on the development of restenosis after coronary balloon angioplasty in postmenopausal women with coronary artery disease.
121. Sullivan JM, Van der Zwaag R, Lemp GF, Hughes JP, Maddock V, Kroetz FW, et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988, 108:358-363.
122. Bourassa PAK, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ: Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1996, 93:10022-10027.
123. Adams MR, Register TC, Golden DL, Wagner JD, Williams KD: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:217-221.
124. Register TC, Adams MR, Golden DL, Clarkson TB: Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998, 18:1164-1171.
125. Barrett-Conner E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer P, et al.: Hormone and nonhormone therapy for the maintenance of postmenopausal health. The need for randomized controlled trials of estrogen and raloxifene. J Womens Health 1998, 7:839-847.
126. Clarkson TB, Anthony MS, Jerome CP: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998, 83:721-726. This important study showed that long-term treatment with the ER modulator raloxifene, in contrast to estrogen therapy, had no effect on the development of coronary artery disease in female nonhuman primates.
127. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613.
128. Schwartz SM, DeBlois D, O'Brien ERM: The intima: Soil for atherosclerosis and restenosis. Circ Res 1995, 77:445-465.
129. Shi Y, O'Brien JE, Ala-Kokko L, Chung W, Mannion JD, Zalewski A: Origin of extracellular matrix synthesis during coronary repair. Circulation 1997, 95:997-1006.
130. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S: Medroxy-progesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996, 94:2221-2227.
131. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL: Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998, 101:1225-1232.
132. Li G, Chen YF, Oparil S, Thompson JA: Estrogen indirectly inhibits adventitial fibroblast migration. Circulation (in press).